In the univariate analysis, a high serum KL-6 level (> 436 U/mL) and a high CRP level (> 0.3 mg/dL) were candidate risk factors for developing severe TR-ILD among patients with lung cancer of categories 1 and 2 (Fig. 4a). This evidence concerns the gene CRP and lung cancer.